Saturday, February 03, 2018 12:21:47 PM
Good exposure for potential of TLR-9s in checkpoint combo immunotherapy. Study used Dynavax's SD-101 in combo with OX-40 mAb. Limited comparative data with IMO-2125, but in PD-1 R/R melanoma so far, IMO+ipi showing 50% ORR (5/10) versus 17% (2/12) for SD-101+pembro (100% ORR 7/7 for SD-101+pembro in PD-1 naive). Should see IMO+pembro data in PD-1 R/R soon to make meaningful comparison.
No pre-clinical of IMO+OX-40 to date, but proven synergy with other checkpoints, notably IDO1.
http://stm.sciencemag.org/content/10/426/eaan4488
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM